Thomas C. Hardin

754 total citations
40 papers, 603 citations indexed

About

Thomas C. Hardin is a scholar working on Epidemiology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Thomas C. Hardin has authored 40 papers receiving a total of 603 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 10 papers in Infectious Diseases and 10 papers in Pharmacology. Recurrent topics in Thomas C. Hardin's work include Antibiotics Pharmacokinetics and Efficacy (10 papers), Antibiotic Resistance in Bacteria (8 papers) and Inflammatory Bowel Disease (5 papers). Thomas C. Hardin is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (10 papers), Antibiotic Resistance in Bacteria (8 papers) and Inflammatory Bowel Disease (5 papers). Thomas C. Hardin collaborates with scholars based in United States and Argentina. Thomas C. Hardin's co-authors include David S. Burgess, James H. Jorgensen, Jan E. Patterson, Jean A. Smith, Kelly Echevarria, Michael G. Rinaldi, Ronald G. Hall, John F. Hansbrough, Donald E. Novicki and Deborah Erickson and has published in prestigious journals such as Gastroenterology, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Thomas C. Hardin

35 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas C. Hardin United States 14 210 175 174 152 123 40 603
B Hampel Germany 16 333 1.6× 161 0.9× 359 2.1× 109 0.7× 59 0.5× 26 876
Federica Pavan Italy 14 419 2.0× 120 0.7× 167 1.0× 168 1.1× 64 0.5× 23 674
Stefanie Swoboda Germany 15 284 1.4× 105 0.6× 168 1.0× 255 1.7× 67 0.5× 32 644
Glenn S. Tillotson United States 15 283 1.3× 142 0.8× 414 2.4× 127 0.8× 81 0.7× 38 826
Mark A. Gill United States 17 422 2.0× 157 0.9× 199 1.1× 114 0.8× 63 0.5× 60 987
Peggy Gandia France 16 404 1.9× 152 0.9× 293 1.7× 143 0.9× 100 0.8× 75 1.0k
Lucie Seyler Belgium 11 369 1.8× 161 0.9× 201 1.2× 103 0.7× 150 1.2× 22 552
Helmi Sulaiman Malaysia 8 216 1.0× 115 0.7× 185 1.1× 90 0.6× 92 0.7× 32 493
Sumathi Nambiar United States 17 241 1.1× 181 1.0× 241 1.4× 188 1.2× 97 0.8× 37 911
Sylva H. Collins United States 5 215 1.0× 242 1.4× 174 1.0× 93 0.6× 137 1.1× 8 409

Countries citing papers authored by Thomas C. Hardin

Since Specialization
Citations

This map shows the geographic impact of Thomas C. Hardin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas C. Hardin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas C. Hardin more than expected).

Fields of papers citing papers by Thomas C. Hardin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas C. Hardin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas C. Hardin. The network helps show where Thomas C. Hardin may publish in the future.

Co-authorship network of co-authors of Thomas C. Hardin

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas C. Hardin. A scholar is included among the top collaborators of Thomas C. Hardin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas C. Hardin. Thomas C. Hardin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bernett, Jorge R, et al.. (2020). 614. Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections and Bacteremia in Infectious Disease Outpatient Infusion Clinics. Open Forum Infectious Diseases. 7(Supplement_1). S367–S367.
2.
Adams, John S., Richard Mandel, Robin Dretler, et al.. (2019). 750. Serious Bacterial Infections: Successful Outpatient Management by Infectious Disease Physicians in Office Infusion Centers. Open Forum Infectious Diseases. 6(Supplement_2). S334–S335.
3.
Schroeder, Claudia P., et al.. (2019). 2494. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs). Open Forum Infectious Diseases. 6(Supplement_2). S865–S865. 2 indexed citations
4.
Ritter, Timothy E., et al.. (2018). Failure of Vedolizumab as First-Line Biologic Does Not Decrease Response Rates of Second-Line Therapy. The American Journal of Gastroenterology. 113(Supplement). S382–S383. 6 indexed citations
5.
Lacy, Melinda K., Martín E. Stryjewski, Whedy Wang, et al.. (2015). Telavancin Hospital-Acquired Pneumonia Trials: Impact of Gram-Negative Infections and Inadequate Gram-Negative Coverage on Clinical Efficacy and All-Cause Mortality. Clinical Infectious Diseases. 61(suppl 2). S87–S93. 19 indexed citations
6.
Burgess, David S., Ronald G. Hall, & Thomas C. Hardin. (2003). In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease. 46(2). 131–137. 25 indexed citations
7.
Burgess, David S., et al.. (2000). Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clinical Therapeutics. 22(1). 66–75. 62 indexed citations
8.
Patterson, Jan E., et al.. (2000). Association of Antibiotic Utilization Measures and Control of Multiple-Drug Resistance inKlebsiella pneumoniae. Infection Control and Hospital Epidemiology. 21(7). 455–458. 130 indexed citations
9.
Burgess, David S., et al.. (2000). Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans☆. Diagnostic Microbiology and Infectious Disease. 36(1). 13–18. 45 indexed citations
10.
Williams, Robert O., et al.. (2000). Trends in antifungal research. Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions. 89. 55–68. 1 indexed citations
11.
Burgess, David S., et al.. (1999). Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Clinical Therapeutics. 21(11). 1882–1889. 21 indexed citations
12.
Hardin, Thomas C., et al.. (1998). Treatment of Thrush with Itraconazole Solution: Evidence for Topical Effect. Clinical Infectious Diseases. 26(5). 1242–1243. 8 indexed citations
13.
Graybill, John R., Laura K. Najvar, Annette W. Fothergill, et al.. (1998). KY-62, a Polyene Analog of Amphotericin B, for Treatment of Murine Candidiasis. Antimicrobial Agents and Chemotherapy. 42(1). 147–150. 14 indexed citations
14.
Hardin, Thomas C.. (1998). In Search of an Ideal Systemic Antifungal Agent. 3(3). 69–83. 2 indexed citations
15.
Hardin, Thomas C., et al.. (1993). Nutritional Parameters Observed During 28‐Day Infusion of Recombinant Human Tumor Necrosis Factor‐α. Journal of Parenteral and Enteral Nutrition. 17(6). 541–545. 3 indexed citations
16.
Hardin, Thomas C., et al.. (1992). AMINOGLYCOSIDES, IMIPENEM, AND AZTREONAM. Clinics in Podiatric Medicine and Surgery. 9(2). 443–464. 2 indexed citations
17.
Hardin, Thomas C., et al.. (1991). Sepsis. Journal of Pharmacy Practice. 4(4). 269–280.
18.
Hardin, Thomas C., et al.. (1990). The Use of Vasopressin in the Treatment of Upper Gastrointestinal Haemorrhage. Drugs. 39(1). 38–53. 23 indexed citations
19.
Hardin, Thomas C., et al.. (1988). Cancer Cachexia. Nutrition in Clinical Practice. 3(5). 191–197. 1 indexed citations
20.
Hardin, Thomas C., et al.. (1982). Desipramine-Induced Agranulocytosis a Case Report. Drug Intelligence & Clinical Pharmacy. 16(1). 62–63. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B Hampel Breakdown of academic impact, for papers by Federica Pavan Breakdown of academic impact, for papers by Stefanie Swoboda Breakdown of academic impact, for papers by Glenn S. Tillotson Breakdown of academic impact, for papers by Mark A. Gill Breakdown of academic impact, for papers by Peggy Gandia Breakdown of academic impact, for papers by Lucie Seyler Breakdown of academic impact, for papers by Helmi Sulaiman Breakdown of academic impact, for papers by Sumathi Nambiar Breakdown of academic impact, for papers by Sylva H. Collins
Rankless by CCL
2026